62 completed, 6 recruiting, 6 terminated, 6 unknown. 46 Phase 1, 22 Phase 4, 10 Phase 2, 5 Not applicable, 3 Phase 3.
Follow Alprazolam: new trials by email Literature Review of Alprazolam trials Research Report on Alprazolam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Role of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment. To Compare Mean Pain Score Between Two Group of Participants Undergoing Post Operative Pain Management After Single Visit Root Canal Treatment: NSAIDs Alone and a Combination of NSAIDs and Alprazolam. Brufen and alprazolam, Brufen - Pain | Not applicable | Recruiting | Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi | 110 | 2026-07-30 | 2026-07-28 |
| Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use Experience Alprazolam (Xanax), Placebo, Gabapentin (Neurontin® (Registered Trademark)) - Healthy Non-dependent, Recreational Sedative Users | Phase 4 | Completed | Viatris Inc. | 44 | 2026-06-18 | 2026-09-08 |
| Oral vs IV Sedation for Cataract Surgery in Older Adults Alprazolam, Midazolam - Cataract Surgery, Sedation | Phase 4 | Completed | University of California, San Francisco | 20 | 2025-08-12 | 2026-04-27 |
| Opioid Drug Interaction Study Alprazolam, Oxycodone, Placebo - Drug Interactions, Drug Kinetics | Phase 1 / Phase 2 | Recruiting | Shanna Babalonis, PhD | 25 | 2025-04-01 | 2026-05-14 |
| An Extension Test of Whether to Use Oral Anti-anxiety Drugs (Alprazolam) When Patients Choose Second Eye Cataract Surgery After Unblinding, and Analyze Their Anxiety, Satisfaction and Pain Satisfaction Alprazolam (Xanax), Placebo Tablets - Ophthalmology, Cataract Surgery Anesthesia | Phase 4 | Recruiting | National Taiwan University Hospital | 250 | 2025-03-25 | 2026-04-24 |
| Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor Alcohol, Alprazolam, Cold Therapy - Essential Tremor | Recruiting | The Cleveland Clinic | 55 | 2024-03-25 | 2026-05-08 | |
| Opioid/Benzodiazepine Polydrug Abuse: Aim 3 Morphine, Alprazolam, Placebo - Opioid Abuse, Benzodiazepine Abuse | Phase 2 | Recruiting | Wayne State University | 24 | 2024-03-13 | 2025-12-30 |
| Detoxification From the Lipid Tract electroencephalogram biofeedback, electrical brain stimulation, ultra-low frequency transcranial magnetic stimulation - COVID-19 Vaccine Adverse Reaction | Phase 4 | Completed | Pachankis, Yang I., M.D. | 1 | 2024-02-26 | 2024-04-10 |
| Anxiety and Surgery Satisfaction for Cataract Patient With Different State Anxiety Xanax, placebo tablets - Oral Anxiolytic, Phacoemulsification | Not applicable | Recruiting | National Taiwan University Hospital | 400 | 2024-01-02 | 2026-04-23 |
| Efficacy of Hydroxyzine for Patients With Panic Disorder Hydroxyzine, Escitalopram Oxalate - Panic Disorder | Phase 4 | Not yet recruiting | Sultan Qaboos University | 80 | 2023-12-30 | 2023-02-21 |
| A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants Staccato alprazolam, Oral alprazolam - Healthy Participants | Phase 1 | Completed | UCB Biopharma SRL | 21 | 2022-12-28 | 2024-03-18 |
| A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience Soticlestat 300 mg, Soticlestat 600 mg, Soticlestat 900 mg - Healthy Volunteers | Phase 1 | Completed | Takeda | 100 | 2022-11-15 | 2026-09-16 |
| An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users Placebo, Alprazolam 2 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg - Abuse Potential | Phase 4 | Completed | Arbor Pharmaceuticals, Inc. | 86 | 2021-09-28 | 2024-08-12 |
| Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim Placebo (Lactose) Capsule, 0.75 mg Alprazolam Capsule, Cannabis (6.18% THC / <0.025% CBD) - Driving Behavior, Driving Under the Influence | Phase 1 | Completed | Timothy L. Brown | 13 | 2021-07-16 | 2023-07-25 |
| A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy Alprazolam - Epilepsy | Phase 1 | Completed | UCB Biopharma SRL | 14 | 2021-04-28 | 2022-06-30 |
| A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma Alprazolam, Placebo - Healthy Study Participants, Participants With Mild Asthma | Phase 1 | Completed | UCB Biopharma SRL | 78 | 2021-03-09 | 2023-11-28 |
| Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants Alprazolam, Placebo - Healthy Study Participants | Phase 1 | Completed | UCB Biopharma SRL | 30 | 2021-03-04 | 2021-05-17 |
| Role of Alprazolam in the Management of Acute Coronary Syndrome Alprazolam, Placebo - Acute Coronary Syndrome, Myocardial Infarction | Phase 1 / Phase 2 | Unknown | Sohaib Ashraf | 48 | 2020-12-25 | 2021-01-20 |
| A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects CVL-865 High dose, Alprazolam 1mg XR, Placebo - Panic Disorder | Phase 1 | Completed | Cerevel Therapeutics, LLC | 56 | 2020-10-06 | 2022-01-11 |
| Preoperative Use of Alprazolam and Hydroxyzine in Anxiety Hydroxyzine Hydrochloride, Alprazolam tablet, Placebo - Agitation on Recovery From Sedation | Phase 4 | Unknown | Istanbul Medeniyet University | 90 | 2019-12-01 | 2019-12-06 |
Showing 20 of 84. Sign in to see all of them.
Anxiety Disorders (21) · Panic Disorder (8) · Generalized Anxiety Disorder (4) · Depression (3) · Diabetes Mellitus, Type 1 (3) · Pain (3) · Motor Activity (2) · Opioid-Related Disorders (2) · Substance-Related Disorders (2) · Acute Coronary Syndrome (1) · Alzheimer Disease (1) · Dementia (1) · Depressive Disorder (1) · Driving Under the Influence (1) · Emergence Delirium (1)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (11) · GlaxoSmithKline (5) · Actavis Inc. (4) · Pfizer (4) · UCB Biopharma SRL (4) · Mylan Pharmaceuticals Inc (3) · Eli Lilly and Company (2) · Isfahan University of Medical Sciences (2) · Mclean Hospital (2) · National Institute on Drug Abuse (NIDA) (2) · National Taiwan University Hospital (2) · Orion Corporation, Orion Pharma (2) · Sandoz (2) · Teva Pharmaceuticals USA (2) · Timothy L. Brown (2)
United States (44) · Canada (4) · France (3) · Finland (2) · Germany (2) · Iran (2) · Mexico (2) · Pakistan (2) · Taiwan (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · Brazil (1) · China (1) · India (1)
James D. Carlson,, Pharm.D, (4) · Dorian Williams, M.D. (3) · James D. Carlson, Pharm. D. (2) · Ahmad Shavakhi, M.D. (1) · Aila Holopainen, M. Sc. (1) · Aila Holopainen, M.Sc. (1) · Balkrishna Bhattarai, MD (1) · Barbara O. Rothbaum, PhD, ABPP (1) · Calvin F. Fuhrmann, M.D. (1) · Catherine L Chen, MD, MPH (1) · Chiun Ho Hou, Ph.D (1)
PMID 10193207, PMID 12567277, PMID 1409977, PMID 16142633, PMID 16320215, PMID 16360929, PMID 16441069, PMID 16876832, PMID 16930894, PMID 17562493, PMID 18176908, PMID 18793913, PMID 20877555, PMID 20877556, PMID 21742023, PMID 22828921, PMID 24338551, PMID 24527443, PMID 24625685, PMID 24743802, PMID 24977401, PMID 25199955, PMID 25901095, PMID 26004882, PMID 27183343, PMID 29017144, PMID 29671186, PMID 29710504, PMID 30059794, PMID 30834253, PMID 32416996, PMID 34423904, PMID 34635547, PMID 39541522, PMID 41747804, PMID 8255929, PMID 9619110
2017 (1), K01DA023659 (1), R01DA016718 (1), R01MH070880 (1), R01MH075792 (1), R36DA043714 (1)